Nedjad Losic

2.3k citations

23 papers · 871 indexed · h-index 10

Impact in

Genetics top 2%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 9
- Chronic Lymphocytic Leukemia Research 9
Pathology and Forensic Medicine 9
- Lymphoma Diagnosis and Treatment 9

Co-authors: Tadeusz Robak Andrzej Hellmann Randy Davis Magdalena Piotrowska Stephan Stilgenbauer Peter Hillmen Thomas J. Kipps Tomáš Kozák
Journals: Journal of Clinical Oncology (6 papers)Blood (6 papers)Annals of Oncology (3 papers)Clinical Pharmacokinetics (2 papers)Cancer Research (1 paper)
Partner nations: United States Denmark Belgium

In The Last Decade

Nedjad Losic

22 papers receiving 856 citations

Peers

Countries citing papers authored by Nedjad Losic

Since Specialization

Citations

This map shows the geographic impact of Nedjad Losic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nedjad Losic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nedjad Losic more than expected).

Fields of papers citing papers by Nedjad Losic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nedjad Losic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nedjad Losic. The network helps show where Nedjad Losic may publish in the future.

Co-authors

The 25 scholars most cited alongside Nedjad Losic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nedjad Losic Line = papers co-authored together Nedjad Losic links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer Clinical Cancer Research ·Eric Van Cutsem, Joëlle Collignon, Rikke Løvendahl Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, Andrew Baird, Dirk Arnold, Analisa Maglov, Per Pfeiffer, Jeffrey Yachnin, 啓介村木, 献三紀伊国, Annika Sanfridson, Nedjad Losic, Ignacio Garcia‐Ribas, Dominique Tersago, Ahmad Awada	2024	2
2	1012P Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors Annals of Oncology ·Roger B. Cohen, Tejas S Kumar, Antonio Jimeno, 大助辻野, L. Sun, Marie Öhman, Annika Sanfridson, Nedjad Losic, Dominique Tersago	2024	0
3	406P Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC Annals of Oncology ·Sara López‐Tarruella, Agostina Stradella, Aiman Salah ud Din, Silvia Antolín, Marta Santisteban, Javier García-Corbacho, Fayçal Bouraoui, Manuel Ruíz Borrego, Andrew Rambaut, Nedjad Losic, Jia Feng, Aleksandr Vladimirovich Khromov, Ryuutarou Mori, J.J. Soto Castillo, Manuel Alva Bianchi, 高橋千幸, María Isabel Casas, 涼岸本, 金始原, Mauchumi Borah	2023	2
4	Abstract 2172: Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel Cancer Research ·Eric Van Cutsem, Joëlle Collignon, Rikke Løvendahl Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, Audrius Ivanauskas, Camilla Rydberg Millrud, Aleksandr Vladimirovich Khromov, Nedjad Losic, 啓介村木, Annika Sanfridson, David Liberg	2023	2
5	Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·Е. В. Белобородова, Patrícia M Rheder, Zanete Zvirbule, Luis Paz‐Ares, Ahmad Awada, Ignacio Garcia‐Ribas, Nedjad Losic, Marius Žemaitis	2022	6
6	Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). Journal of Clinical Oncology ·Eric Van Cutsem, Rikke Løvendahl Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, Andrew Baird, Dirk Arnold, Analisa Maglov, Per Pfeiffer, Jeffrey Yachnin, Rocio García‐Carbonero, Richard Greil, Christiane Jungels, Laurids Østergaard Poulsen, Ahmad Awada, Ignacio Garcia‐Ribas, Nedjad Losic, Joëlle Collignon	2022	5
7	963MO Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201 Annals of Oncology ·Jaume Mora, Misty D. Bear, Gcf Chan, Daniel A. Morgenstern, Karsten Nysom, Karen Tornøe, Nedjad Losic, Brian H. Kushner	2021	4
8	Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease. Journal of Clinical Oncology ·Brian H. Kushner, Daniel A. Morgenstern, Karsten Nysom, ʿAskar Ḥuqūqī, Karen Tornøe, Nedjad Losic, Jaume Mora	2021	4
9	Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies Blood ·Ida H. Hiemstra, Patrick Engelberts, Georgina Blanco-Mancilla, Danita H. Schuurhuis, Theodora W. Salcedo, Sandra Verploegen, Marten van der Zee, Arnout F. Gerritsen, Nedjad Losic, Paul Hinrichs, Roberto S Oliveri, Jeroen J. Lammerts van Bueren, Pernille A. Usher, Janine Schuurman, Paul W.H.I. Parren, Esther C.W. Breij	2018	2
10	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma Clinical Pharmacokinetics ·Xiaoyu Yan, Pamela L. Clemens, Thomas A. Puchalski, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson, Torben Plesner, Kevin Liu, Robert Z. Orlowski, Nedjad Losic, Richard K. Jansson, Tahamtan Ahmadi, Kristen Lantz, Juan José Pérez Ruixo, Honghui Zhou, Xu Steven Xu	2017	26
11	GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817). Journal of Clinical Oncology ·Ulrik Lassen, Suresh S. Ramalingam, Juanita Lopez, R. Donald Harvey, Malaka Ameratunga, Jan de Hoon, Nedjad Losic, Steen Lisby, Ulf Forssmann, Ignace Vergote	2017	6
12	Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment Clinical Pharmacokinetics ·Pamela L. Clemens, Xiaoyu Yan, Henk M. Lokhorst, Sagar Lonial, Nedjad Losic, Imran Khan, Richard K. Jansson, Tahamtan Ahmadi, Kristen Lantz, Honghui Zhou, Thomas A. Puchalski, Xu Steven Xu	2016	63
13	Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitor (PI) and Immunomodulatory Drug (IMiD) Treatment Clinical Lymphoma Myeloma & Leukemia ·Pamela L. Clemens, Xiaoyu Yan, Thomas A. Puchalski, H M Lokhorst, Sagar Lonial, Nedjad Losic, Imran Khan, Geske Thomas, Phelix Rufus, Karen Elizabeth Asan, Huifen Zhou, F.J.G.Heyes	2015	2
14	Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study British Journal of Haematology ·Bertrand Coiffier, Nedjad Losic, Birgitte Rønn, Stéphane Leprêtre, Lars Møller Pedersen, Ole Gadeberg, Henrik Frederiksen, Marinus H. J. van Oers, James E. Wooldridge, Janusz Kłoczko, Jerzy Hołowiecki, Andrzej Hellmann, Jan Walewski, Tadeusz Robak, Jørgen Holm Petersen	2010	30
15	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia Journal of Clinical Oncology ·William G. Wierda, Thomas J. Kipps, Jiřı́ Mayer, Stephan Stilgenbauer, Cathy Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trněný, Martin J.S. Dyer, (unknown), Magdalena Piotrowska, Tomáš Kozák, Geoffrey Chan, Randy Davis, Nedjad Losic, Dongxu Li, Charlotte Russell, Anders Österborg	2010	413
16	Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study Blood ·Bertrand Coiffier, André Bosly, Ka Lung Wu, Gregor Verhoef, B.R. Hjortbak, Giovanni Martinelli, M. Espy, Andrew Davies, Eve Gallop‐Evans, Swaminathan P. Iyer, Ira Gupta, Thomas S. Lin, Randy Davis, Nedjad Losic, Steen Lisby, John Radford	2010	13
17	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia Blood ·William G. Wierda, Thomas J. Kipps, Jiřı́ Mayer, Tadeusz Robak, Martin J.S. Dyer, Richard R. Furman, Peter Hillmen, Stephan Stilgenbauer, Catherine Williams, Marek Trněný, Guillaume Cartron, Francisco J. Hernandez‐Ilizaliturri, Swaminathan P. Iyer, Geoffrey Chan, Ira Gupta, M Gorczyca, Randy Davis, Nedjad Losic, Steen Lisby, Anders Österborg	2010	16
18	Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab Clinical Lymphoma & Myeloma ·William G. Wierda, Thomas J. Kipps, Jiřı́ Mayer, Stephan Stilgenbauer, Cathy Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trněný, Martin J.S. Dyer, (unknown), Magdalena Piotrowska, Tomáš Kozák, Geoffrey Chan, Randy Davis, Nedjad Losic, Dongxu Li, Charlotte Russell, Anders Österborg	2009	3
19	Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial Blood ·Anders Österborg, Thomas J. Kipps, Jiřı́ Mayer, Stephan Stilgenbauer, Catherine Williams, G Williams, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trněný, Martin J.S. Dyer, Swaminathan P. Iyer, Tomáš Kozák, Geoffrey Chan, Randy Davis, Nedjad Losic, Charlotte Russell, Magdalena Piotrowska, Dongxu Li, William G. Wierda	2008	35
20	Incorporation of a stopping criterion for futility into the design of a clinical trial with one interim analysis Communication in Statistics- Theory and Methods ·Ulf Strömberg, Nedjad Losic, Jan Lanke	1997	2

About Nedjad Losic

Nedjad Losic is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 23 papers that have together received 871 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Cancer Immunotherapy and Biomarkers (5 papers), Peptidase Inhibition and Analysis (4 papers), Multiple Myeloma Research and Treatments (4 papers), Neuroblastoma Research and Treatments (4 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). The work is most often cited by research in Genetics (547 citations), Pathology and Forensic Medicine (551 citations), Hematology (168 citations), Immunology (304 citations) and Radiology, Nuclear Medicine and Imaging (243 citations). Nedjad Losic has collaborated with scholars based in United States, Denmark and Belgium. Frequent co-authors include Tadeusz Robak, Andrzej Hellmann, Randy Davis, Magdalena Piotrowska, Stephan Stilgenbauer, Peter Hillmen, Thomas J. Kipps, Tomáš Kozák, Geoffrey Chan and Martin J.S. Dyer. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, Clinical Pharmacokinetics and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact